Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Jan 2, 2026 22:24 UTC |
Trepeta SeanDirector · Pres of Mobiquity Networks
|
GrantCommon Stock Options · Derivative | 100,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000043 · ownership.xml · derivative · entry 1 Trepeta Sean · CIK 0001538450 · Director · Pres of Mobiquity Networks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,117 Underlying: Common Stock · 100,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:24 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock Options · Derivative | 250,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000041 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 761,544 Underlying: Common Stock · 250,000 shares Expires 2030-12-31 F1 · price: Not applicable. F2 · balance_after: Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share, (iv)100,000 shares underlying a convertible note at $1.00 per share, (v) options to purchase 250,000 shares exercisable at $2.45 per share, and (vi) options to purchase 250,000 exercisable at $1.10 per share. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:23 UTC |
Provost Anne SchmidtDirector
|
GrantCommon Stock Options · Derivative | 50,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000039 · ownership.xml · derivative · entry 1 Provost Anne Schmidt · CIK 0001919163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,667 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:23 UTC | GrantCommon Stock Options · Derivative | 100,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000038 · ownership.xml · derivative · entry 1 McDonnell Sean · CIK 0001318020 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,867 Underlying: Common Stock · 100,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
|
| December 31, 2025 Filed Jan 2, 2026 22:23 UTC |
Knight NateDirector
|
GrantCommon Stock Options · Derivative | 50,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000037 · ownership.xml · derivative · entry 1 Knight Nate · CIK 0001584877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,667 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:22 UTC |
Julia Dean L.Director · CEO
|
GrantCommon Stock Options · Derivative | 350,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000035 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,775,817 Underlying: Common Stock · 350,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:22 UTC |
Booker Stuart ByronDirector
|
GrantCommon Stock Options · Derivative | 50,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000034 · ownership.xml · derivative · entry 1 Booker Stuart Byron · CIK 0001972532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,667 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 22:22 UTC |
Bauersfeld PaulChief Technology Officer
|
GrantCommon Stock Options · Derivative | 100,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001683168-26-000033 · ownership.xml · derivative · entry 1 Bauersfeld Paul · CIK 0001629264 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,183 Underlying: Common Stock · 100,000 shares Expires 2030-12-31 F1 · price: Not applicable. Read SEC document |
| September 15, 2025 Filed Sep 19, 2025 21:00 UTC |
Salkind GeneDirector · 10% owner
|
GrantConvertible notes · Derivative | 100,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001683168-25-007156 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 511,544 Underlying: Common Stock · 100,000 shares Expires 2025-10-17 F2 · security: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust. F3 · price: Not applicable. F4 · balance_after: Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share, (iv)100,000 shares underlying a convertible note at $1.00 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share. Read SEC document |
| September 15, 2025 Filed Sep 19, 2025 21:00 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 25,000 | $1.00 | $25,000.00 |
DisclosureSEC source: 0001683168-25-007156 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,668,695 F1 · security: Represents interest paid on a convertible note F2 · balance_after: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 21:05 UTC |
Salkind GeneDirector · 10% owner
|
OtherConvertible notes · Derivative | 210,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001683168-25-000023 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,544 Underlying: Common Stock · 420,000 shares Expires 2024-12-31 F2 · security: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust. F1 · price: Not applicable. F3 · balance_after: Includes (i) 59,211 shares underlying warrants exercisable at $60 per share, (ii) 2,333 shares underlying options exercisable at $68.48 per share, (iii) 100,000 shares underlying options exercisable at $.20 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 21:05 UTC |
Salkind GeneDirector · 10% owner
|
OtherCommon Stock | 420,000 | $0.50 | $210,000.00 |
DisclosureSEC source: 0001683168-25-000023 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,643,695 F2 · balance_after: The securities listed in Table I and Table II are securities owned directly by Dr. Salkind and his wife and by a family trust. Read SEC document |
| October 08, 2024 Filed Oct 22, 2024 01:59 UTC |
Bauersfeld PaulChief Technology Officer
|
GrantCommon Stock Options · Derivative | 150,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007279 · ownership.xml · derivative · entry 1 Bauersfeld Paul · CIK 0001629264 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,183 Underlying: Common Stock · 150,000 shares Expires 2029-10-08 F1 · price: Not applicable Read SEC document |
| October 08, 2024 Filed Oct 22, 2024 01:59 UTC |
Julia Dean L.Director · CEO
|
GrantCommon Stock Options · Derivative | 450,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007277 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,425,817 Underlying: Common Stock · 450,000 shares Expires 2029-10-08 F1 · price: Not applicable Read SEC document |
| October 08, 2024 Filed Oct 22, 2024 01:47 UTC |
Provost Anne SchmidtDirector
|
GrantCommon stock options · Derivative | 50,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007275 · ownership.xml · derivative · entry 1 Provost Anne Schmidt · CIK 0001919163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,667 Underlying: Common stock · 50,000 shares Expires 2029-10-08 F1 · price: Not applicable. Read SEC document |
| October 08, 2024 Filed Oct 22, 2024 01:46 UTC |
Knight NateDirector
|
GrantCommon stock options · Derivative | 50,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007274 · ownership.xml · derivative · entry 1 Knight Nate · CIK 0001584877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,667 Underlying: Common stock · 50,000 shares Expires 2029-10-08 F1 · price: Not applicable. Read SEC document |
| October 08, 2024 Filed Oct 22, 2024 01:44 UTC | GrantCommon Stock Options · Derivative | 50,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007271 · ownership.xml · derivative · entry 1 McDonnell Sean · CIK 0001318020 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,867 Underlying: Common Stock · 50,000 shares Expires 2029-10-08 F1 · price: Not applicable Read SEC document |
|
| October 08, 2024 Filed Oct 22, 2024 01:39 UTC |
Trepeta SeanDirector · Pres of Mobiquity Networks
|
GrantCommon Stock Options · Derivative | 100,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007269 · ownership.xml · derivative · entry 1 Trepeta Sean · CIK 0001538450 · Director · Pres of Mobiquity Networks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,117 Underlying: Common Stock · 100,000 shares Expires 2029-10-08 F1 · price: Not applicable Read SEC document |
| October 08, 2024 Filed Oct 21, 2024 23:53 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock Options · Derivative | 250,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007267 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,544 Underlying: Common Stock · 250,000 shares Expires 2029-10-08 F2 · security: The securities listed in Table II are securities owned directly by Dr. Salkind and his wife and by a family trust. F1 · price: Not applicable. F3 · balance_after: Includes (i) 420,000 common shares underlying convertible notes, (ii) 59,211 shares underlying warrants exercisable at $60 per share, (iii) 2,333 shares underlying options exercisable at $68.48 per share, (iv) 100,000 shares underlying options exercisable at $.20 per share and (v) options to purchase 250,000 shares exercisable at $2.45 per share. Read SEC document |
| October 08, 2024 Filed Oct 21, 2024 23:53 UTC |
Booker Stuart ByronDirector
|
GrantCommon stock options · Derivative | 50,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001683168-24-007266 · ownership.xml · derivative · entry 1 Booker Stuart Byron · CIK 0001972532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,667 Underlying: Common stock · 50,000 shares Expires 2029-10-08 F1 · price: Not applicable. Read SEC document |
| August 06, 2024 Filed Aug 9, 2024 00:19 UTC |
Salkind GeneDirector · 10% owner
|
ConversionSeries H Preferred Stock · Derivative | 751,973 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-24-005385 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 616,201 Underlying: Common Stock · 7,519,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust. F1 · derivative.expiration_date: Not applicable. Read SEC document |
| August 06, 2024 Filed Aug 9, 2024 00:19 UTC |
Salkind GeneDirector · 10% owner
|
ConversionCommon Stock | 7,675,160 | $0.20 | $1,535,032.00 |
DisclosureSEC source: 0001683168-24-005385 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,223,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Includes dividend shares issued upon conversion. F2 · ownership.direct: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust. Read SEC document |
| August 06, 2024 Filed Aug 22, 2024 20:00 UTC Amendment |
Salkind GeneDirector · 10% owner
|
ConversionSeries H Preferred Stock · Derivative | 751,973 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-24-005963 · salkind_f4.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,544 Underlying: Common Stock · 7,519,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust. F1 · derivative.expiration_date: Not applicable. F4 · balance_after: Includes (i) 420,000 common shares underlying convertible notes, (ii) 59,211 shares underlying warrants exercisable at $60 per share, (iii) 2,333 shares underlying options exercisable at $68.48 per share and (iv) 100,000 shares underlying options exercisable at $.20 per share. Read SEC document |
| August 06, 2024 Filed Aug 22, 2024 20:00 UTC Amendment |
Salkind GeneDirector · 10% owner
|
ConversionCommon Stock | 7,675,160 | $0.20 | $1,535,032.00 |
DisclosureSEC source: 0001683168-24-005963 · salkind_f4.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,223,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Includes dividend shares issued upon conversion. F2 · ownership.direct: The securities listed in Table I and II are securities owned directly by Dr. Salkind and his wife and by a family trust. Read SEC document |
| July 25, 2024 Filed Jul 30, 2024 01:38 UTC |
Salkind GeneDirector · 10% owner
|
GrantConvertible Promissory Notes · Derivative | 50,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001683168-24-005116 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,931 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. F1 · derivative.expiration_date: Not applicable. Read SEC document |
| June 27, 2024 Filed Jul 2, 2024 01:30 UTC |
Salkind GeneDirector · 10% owner
|
GrantConvertible Promissory Notes · Derivative | 160,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001683168-24-004578 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,035,931 Underlying: Common Stock · 320,000 shares Expires not disclosed F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. F1 · derivative.expiration_date: Not applicable. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 00:08 UTC |
Trepeta SeanDirector · Pres of Mobiquity Networks
|
GrantCommon Stock Options · Derivative | 50,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008977 · ownership.xml · derivative · entry 1 Trepeta Sean · CIK 0001538450 · Director · Pres of Mobiquity Networks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,117 Underlying: Common Stock · 50,000 shares Expires 2028-12-19 F1 · price: Not applicable Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 00:08 UTC | GrantCommon Stock Options · Derivative | 50,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008976 · ownership.xml · derivative · entry 1 McDonnell Sean · CIK 0001318020 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,867 Underlying: Common Stock · 50,000 shares Expires 2028-12-19 F1 · price: Not applicable Read SEC document |
|
| December 19, 2023 Filed Dec 19, 2023 23:08 UTC |
Bauersfeld PaulChief Technology Officer
|
GrantCommon Stock Options · Derivative | 150,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008974 · ownership.xml · derivative · entry 1 Bauersfeld Paul · CIK 0001629264 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,183 Underlying: Common Stock · 150,000 shares Expires 2028-12-19 F1 · price: Not applicable Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 22:28 UTC |
Julia Dean L.Director · CEO
|
GrantCommon Stock Options · Derivative | 950,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008973 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975,817 Underlying: Common Stock · 950,000 shares Expires 2028-12-19 F1 · price: Not applicable Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 22:12 UTC |
Booker Stuart ByronDirector
|
GrantCommon stock options · Derivative | 50,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008969 · ownership.xml · derivative · entry 1 Booker Stuart Byron · CIK 0001972532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 Underlying: Common stock · 50,000 shares Expires 2028-12-19 F1 · price: Not applicable. Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 22:12 UTC |
Provost Anne SchmidtDirector
|
GrantCommon stock options · Derivative | 50,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008971 · ownership.xml · derivative · entry 1 Provost Anne Schmidt · CIK 0001919163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 Underlying: Common stock · 50,000 shares Expires 2028-12-19 F1 · price: Not applicable. Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 22:11 UTC |
Knight NateDirector
|
GrantCommon stock options · Derivative | 50,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008967 · ownership.xml · derivative · entry 1 Knight Nate · CIK 0001584877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 Underlying: Common stock · 50,000 shares Expires 2028-12-19 F1 · price: Not applicable. Read SEC document |
| December 19, 2023 Filed Dec 19, 2023 22:00 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon stock options · Derivative | 100,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008965 · ownership.xml · derivative · entry 3 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,715,931 Underlying: Common Stock · 100,000 shares Expires 2028-12-19 F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:00 UTC |
Salkind GeneDirector · 10% owner
|
Disposition to issuerPreferred Stock Series H · Derivative | 751,973 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001683168-23-008965 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,615,931 Underlying: Common Stock · 7,519,730 shares Expires not disclosed F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495. F1 · derivative.expiration_date: Not applicable. F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:00 UTC |
Salkind GeneDirector · 10% owner
|
GrantPreferred Stock Series G · Derivative | 300,789 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001683168-23-008965 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,103,990 Underlying: Common Stock · 3,007,789 shares Expires not disclosed F2 · price: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495. F1 · derivative.expiration_date: Not applicable. F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by a family trust. Salkind and the trust exchanged Series G preferred stock for series H preferred Stock with an issue value of $1,503,495. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 19:41 UTC |
Salkind GeneDirector · 10% owner
|
GrantPreferred Stock · Derivative | 300,789 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001683168-23-007787 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,103,990 Underlying: Common Stock · 3,007,890 shares Expires not disclosed F3 · security: Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share. F3 · price: Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share. F1 · derivative.expiration_date: Not applicable. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 19:41 UTC |
Salkind GeneDirector · 10% owner
|
Exercise / conversionCommon Stock · Derivative | Not disclosed | Not disclosed Strike: $0.70 | $300,000.00 |
DisclosureSEC source: 0001683168-23-007787 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,100 Underlying: Common Stock · 428,571 shares Expires 2023-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share. F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023. Read SEC document |
| October 06, 2023 Filed Oct 11, 2023 00:18 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 150,000 | $0.65 | $97,500.00 |
DisclosureSEC source: 0001683168-23-007040 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,535 F1 · security: The 448,535 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. Read SEC document |
| October 06, 2023 Filed Nov 9, 2023 19:40 UTC Amendment |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock · Derivative | Not disclosed | Not disclosed Strike: $0.70 | $300,000.00 |
DisclosureSEC source: 0001683168-23-007786 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,671 Underlying: Common Stock · 428,571 shares Expires 2023-11-30 F3 · price: Not applicable. F2 · balance_after: The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023. Read SEC document |
| October 06, 2023 Filed Nov 9, 2023 19:40 UTC Amendment |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 150,000 | $0.65 | $97,500.00 |
DisclosureSEC source: 0001683168-23-007786 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,535 F1 · security: The 448,535 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 00:42 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 1,385,663 | $0.17 | $235,562.71 |
DisclosureSEC source: 0001683168-23-002368 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,478,017 F1 · security: The 4,478,017 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:53 UTC |
Provost Anne SchmidtDirector
|
GrantCommon Stock | 50,000 | $0.17 | $8,350.00 |
DisclosureSEC source: 0001683168-23-002210 · ownership.xml · nonDerivative · entry 1 Provost Anne Schmidt · CIK 0001919163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:44 UTC |
Julia Dean L.Director · CEO
|
GrantCommon Stock | 50,000 | $0.17 | $8,350.00 |
DisclosureSEC source: 0001683168-23-002204 · ownership.xml · nonDerivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,884 Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:43 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 130,000 | $0.17 | $21,710.00 |
DisclosureSEC source: 0001683168-23-002202 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,092,354 F1 · security: The 3,092,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 20:15 UTC |
Booker Stuart ByronDirector
|
GrantCommon Stock · Derivative | 25,000 | Not disclosed Strike: $0.22 | Not disclosed |
DisclosureSEC source: 0001683168-23-002165 · ownership.xml · derivative · entry 1 Booker Stuart Byron · CIK 0001972532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-04 F1 · price: Not applicable. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 20:44 UTC |
Julia Dean L.Director · CEO
|
GrantCommon Stock Options · Derivative | 12,500 | Not disclosed Strike: $0.16 | Not disclosed |
DisclosureSEC source: 0001683168-23-002204 · ownership.xml · derivative · entry 2 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,250 Underlying: Common Stock · 12,500 shares Expires 2033-04-01 F1 · price: Not applicable Read SEC document |
| March 21, 2023 Filed Apr 4, 2023 18:14 UTC |
Knight NateDirector
|
GrantCommon Stock · Derivative | 25,000 | Not disclosed Strike: $0.22 | Not disclosed |
DisclosureSEC source: 0001683168-23-002131 · ownership.xml · derivative · entry 1 Knight Nate · CIK 0001584877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-21 F1 · price: Not applicable. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 01:34 UTC |
Salkind GeneDirector · 10% owner
|
ConversionWarrants · Derivative | 204,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001683168-22-004784 · ownership.xml · derivative · entry 3 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,441,500 Underlying: Common Stock · 204,000 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. F2 · security: The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029. F3 · price: Not applicable. F5 · balance_after: 1,441,500 derivative securities include the following: (i) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (ii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iii) warrants to purchase 1,015,875 shares exercisable through September 30, 2029 which were issuable on June 30, 2022 as a result of the note conversion. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 01:34 UTC |
Salkind GeneDirector · 10% owner
|
ConversionNotes · Derivative | 510,000 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001683168-22-004784 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 510,000 shares Expires 2029-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. F2 · security: The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029. F3 · price: Not applicable. F4 · balance_after: Left blank intentionally. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.